Amphotericin B-Gum Arabic Conjugates: Synthesis, Toxicity, Bioavailability, and Activities Against Leishmania and Fungi
- 495 Downloads
Gum arabic, a branched polysaccharide consisting of more than 90% arabinogalactan having a molecular weight around 250,000 Da is the oldest and best known of all natural gums. The objective of the present investigation was to examine whether amphotericin B (AmB), the polyene antibiotic when conjugated to periodate oxidized gum arabic still retained its anti-fungal and anti-leishmanial activity and to evaluate its toxicity and bioavailability.
AmB conjugated to the oxidized polysaccharide through Schiff’s linkages in the unreduced (imine) and reduced (amine) forms were characterized for the drug content, hemolytic potential, molecular mass, in vitro release and were examined for anti-fungal activity against Candida albicans and Cryptococcus neoformans and for anti-leishmanial activity against promastigotes of Leishmania donovani in culture. Toxicity and bioavailability were evaluated by intravenous (i.v) injections of the conjugates in mice and rabbits respectively.
The conjugates were found to be non-hemolytic and mice withstood a dosage of 20 mg (AmB)/kg body weight of both conjugates. Histological examination of the internal organs of mice showed no lesions in kidney, brain, heart or liver. Estimation of the residual drug in the internal organs 7 days post injection showed that the spleen still retained 8.4 ± 0.53 μg/g of tissue. AmB was found to be released from both conjugates in vitro although the release from the imine conjugate was much faster than from the amine conjugate. The concentrations inhibiting parasite growth by 50% (IC50) values for the imine conjugate against promastigotes of L. donovani LV9 and DD8 strains were 0.37 ± 0.04 and 1.44 ± 0.18 μM respectively. The IC50 values for the amine conjugates were much higher. The minimum inhibitory concentration (MIC) against C. albicans and C. neoformans was in the range of 0.5–0.9 μg/mL for both imino and amino conjugates. The bioavailability of the conjugate in rabbits showed that the imine conjugate maintained a plasma concentration in the range of 20 to 5 μg/mL while for the amine conjugate it was in the range of 17 to 3 μg/mL over 24 h.
The drug conjugates were stable, non-hemolytic and non-toxic to the internal organs of the animal and showed good anti-fungal and anti-leishmanial activity in vitro. In spite of the large molecular weight of the polysaccharide, AmB from the conjugates showed bioavailability after i.v injection. Since the highest concentration of AmB was found in the spleen after a single injection, these conjugates may have potential in anti-leishmanial therapy.
Key wordsamphotericin B antifungal antileishmanial bioavailability gum arabic hemolysis polymer-drug conjugate toxicity
K. K. Nishi thanks the University Grants Commission, New Delhi for a senior research fellowship. Thanks are due to Dr. Nirmala R. James for the hemolysis experiments and many useful discussions. Thanks are also due to the Director, SCTIMST for permission to publish this manuscript.
- 5.J. Brajtburg, W. G. Powderly, G. S. Kobayashi, and G. Medoff. Mini review. Amphotericin B: current understanding of mechanism of action. Antimicrob. Agent Chemother. 34:183–188 (1990).Google Scholar
- 17.E. Charvalos, M. N. Tzatzarakis, F. V. Bambeke, P. M. Tulkens, A. M. Tsatsakis, G. N. Tzanakakis, and M.-P. Mingeot-Leclercq. Water-soluble amphotericin-B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp and Aspergillus spp and reduced haemolytic and cytotoxic effects. J. Antimicrob. Chemother. 57:236–244 (2006).PubMedCrossRefGoogle Scholar
- 21.National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M-27A. National Committee for Clinical Laboratory Standards, Wayne, PA, 1997.Google Scholar
- 27.M. S. Maddux and A. L. Barriere. A review of complications of amphotericin B therapy: Recommendations for prevention and management. Drug. Intel. Clin. Pharm. 14:177–181 (1980).Google Scholar